- Home
- YALA vs MNMD Comparison
YALA vs MNMD Comparison
Compare YALA & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YALA | MNMD |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United Arab Emirates | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Pharmaceuticals and Biotechnology |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | YALA | MNMD |
|---|---|---|
| Price | $7.09 | $14.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $30.33 |
| AVG Volume (30 Days) | 299.8K | ★ 2.0M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.79 | N/A |
| EPS | ★ 0.82 | N/A |
| Revenue | ★ $348,904,940.00 | N/A |
| Revenue This Year | $3.07 | N/A |
| Revenue Next Year | $11.99 | N/A |
| P/E Ratio | $8.54 | ★ N/A |
| Revenue Growth | ★ 5.80 | N/A |
| 52 Week Low | $3.83 | $4.70 |
| 52 Week High | $9.29 | $14.81 |
Technical Indicators
Market Signals| Indicator | YALA | MNMD |
|---|---|---|
| Relative Strength Index (RSI) | 51.27 | 67.62 |
| Support Level | $6.92 | $13.06 |
| Resistance Level | $7.21 | $14.81 |
| Average True Range (ATR) | 0.19 | 0.84 |
| MACD | 0.00 | 0.11 |
| Stochastic Oscillator | 60.81 | 82.03 |
Price Performance
Historical ComparisonAbout YALA Yalla Group Limited each representing one
Yalla Group Ltd is a MENA-based online social networking and gaming company. It operates two flagship mobile applications, Yalla, a voice-centric group chat platform, and Yalla Ludo, a casual gaming application featuring online versions of board games popular in MENA, with in-game voice chat and localized majlis functions. The Group has one operating segment, which is the social networking and entertainment platform.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).